Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Coupland, Carol; Hill, Trevor; Morriss, Richard; Arthur, Antony; Moore, Michael; Hippisley-Cox, Julia (2015)
Publisher: BMJ Publishing Group Ltd.
Journal: The BMJ
Languages: English
Types: Article
Subjects: Research
Objective \ud \ud To assess the associations between different antidepressant treatments and the rates of suicide and attempted suicide or self harm in people with depression.\ud \ud Design \ud \ud Cohort study.\ud \ud Setting \ud \ud Patients registered with UK general practices contributing data to the QResearch database.\ud \ud Participants 238 963 patients aged 20 to 64 years with a first diagnosis of depression between 1 January 2000 and 31 July 2011, followed up until 1 August 2012.\ud \ud Exposures Antidepressant class (tricyclic and related antidepressants, selective serotonin reuptake inhibitors, other antidepressants), dose, and duration of use, and commonly prescribed individual antidepressant drugs. Cox proportional hazards models were used to calculate hazard ratios adjusting for potential confounding variables.\ud \ud Main outcome measures \ud \ud Suicide and attempted suicide or self harm during follow-up.\ud \ud Results \ud \ud During follow-up, 87.7% (n=209 476) of the cohort received one or more prescriptions for antidepressants. The median duration of treatment was 221 days (interquartile range 79-590 days). During the first five years of follow-up 198 cases of suicide and 5243 cases of attempted suicide or self harm occurred. The difference in suicide rates during periods of treatment with tricyclic and related antidepressants compared with selective serotonin reuptake inhibitors was not significant (adjusted hazard ratio 0.84, 95% confidence interval 0.47 to 1.50), but the suicide rate was significantly increased during periods of treatment with other antidepressants (2.64, 1.74 to 3.99). The hazard ratio for suicide was significantly increased for mirtazapine compared with citalopram (3.70, 2.00 to 6.84). Absolute risks of suicide over one year ranged from 0.02% for amitriptyline to 0.19% for mirtazapine. There was no significant difference in the rate of attempted suicide or self harm with tricyclic antidepressants (0.96, 0.87 to 1.08) compared with selective serotonin reuptake inhibitors, but the rate of attempted suicide or self harm was significantly higher for other antidepressants (1.80, 1.61 to 2.00). The adjusted hazard ratios for attempted suicide or self harm were significantly increased for three of the most commonly prescribed drugs compared with citalopram: venlafaxine (1.85, 1.61 to 2.13), trazodone (1.73, 1.26 to 2.37), and mirtazapine (1.70, 1.44 to 2.02), and significantly reduced for amitriptyline (0.71, 0.59 to 0.85). The absolute risks of attempted suicide or self harm over one year ranged from 1.02% for amitriptyline to 2.96% for venlafaxine. Rates were highest in the first 28 days after starting treatment and remained increased in the first 28 days after stopping treatment.\ud \ud Conclusion \ud \ud Rates of suicide and attempted suicide or self harm were similar during periods of treatment with selective serotonin reuptake inhibitors and tricyclic and related antidepressants. Mirtazapine, venlafaxine, and trazodone were associated with the highest rates of suicide and attempted suicide or self harm, but the number of suicide events was small leading to imprecise estimates. As this is an observational study the findings may reflect indication biases and residual confounding from severity of depression and differing characteristics of patients prescribed these drugs. The increased rates in the first 28 days of starting and stopping antidepressants emphasise the need for careful monitoring of patients during these periods
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1 Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997;170:205-28.
    • 2 Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res 2002;53:849-57.
    • 3 Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, et al. Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev 2009;3:CD007954.
    • 4 Gibbons RD, Hur K, Brown C, Davis JM, Mann J. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012;69:572-9.
    • 5 Friedman RA, Leon AC. Expanding the black box-depression, antidepressants, and the risk of suicide. N Engl J Med 2007;356:2343-6.
    • 6 Hall WD. How have the SSRI antidepressants afected suicide risk? Lancet 2006;367:1959-62.
    • 7 Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009;339:b2880.
    • 8 Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ 2009;180:291-7.
    • 9 Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 2007;334:242.
    • 10 Schneeweiss S, Patrick AR, Solomon DH, Mehta J, Dormuth C, Miller M, et al. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry 2010;67:497-506.
    • 11 Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:d4551.
    • 12 Ofice for National Statistics. Suicides in the United Kingdom, 2011. ONS, 2013.
    • 13 Barr B, Taylor-Robinson D, Scott-Samuel A, McKee M, Stuckler D. Suicides associated with the 2008-10 economic recession in England: time trend analysis. BMJ 2012;345:e5142.
    • 14 Chang S-S, Stuckler D, Yip P, Gunnell D. Impact of 2008 global economic crisis on suicide: time trend study in 54 countries. BMJ 2013;347:f5239.
    • 15 Coupland C, Morriss R, Arthur A, Moore M, Hill T, Hippisley-Cox J. Safety of antidepressants in adults aged under 65: protocol for a cohort study using a large primary care database. BMC Psychiatry 2013;13:135.
    • 16 Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005;330:389.
    • 17 Hippisley-Cox J, Pringle M, Hammersley V, Crown N, Wynn A, Meal A, et al. Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care. BMJ 2001;323:666-9.
    • 18 Hall GC. Validation of death and suicide recording on the THIN UK primary care database. Pharmacoepidemiol Drug Saf 2009;18:120-31.
    • 19 Coupland C, Dhiman P, Barton G, Morriss R, Arthur A, Sach T, et al. A study of the safety and harms of antidepressant drugs for older people: a cohort study analysis using a large primary care database. Health Technol Assess 2011:15(28).
    • 20 Williams RL. A note on robust variance estimation for clustercorrelated data. Biometrics 2000;56:645-6.
    • 21 Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999;319:1492-5.
    • 22 Hawton K, Bergen H, Simkin S, Cooper J, Waters K, Gunnell D, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry 2010;196:354-8.
    • 23 Cameron IM, Lawton K, Reid IC. Recognition and subsequent treatment of patients with sub-threshold symptoms of depression in primary care. J Afect Disord 2011;130:99-105.
    • 24 Terluin B, van Hout HPJ, van Marwijk HWJ, Adèr HJ, van der Meer K, de Haan M, et al. Reliability and validity of the assessment of depression in general practice: the short depression interview (SDI). Gen Hosp Psychiatry 2002;24:396-405.
    • 25 National Institute for Health and Care Excellence. Depression in adults: the treatment and management of depression in adults (update). (Clinical guideline 90.) 2009. www.nice.org.uk/guidance/cg90
    • 26 Hawton K, Casaañs I Comabella C, Haw C, Saunders K. Risk factors for suicide in individuals with depression: a systematic review. J Afect Disord 2013;147:17-28.
    • 27 Gunnell D, Hawton K, Kapur N. Coroners' verdicts and suicide statistics in England and Wales. BMJ 2011;343:d6030.
    • 28 Department of Health. Statistical update on suicide, 2014. DoH. www. gov.uk/government/publications/suicide-prevention-report
    • 29 Mines D, Hill D, Yu H, Novelli L. Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol Drug Saf 2005;14:367-72.
    • 30 Valenstein M, Kim HM, Ganoczy D, Eisenberg D, Pfeiefr PN, Downing K, et al. Antidepressant agents and suicide death among US Department of Veterans Aafirs patients in depression treatment. J Clin Psychopharmacol 2012;32:346-53.
    • 31 Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006;63:1358-67.
    • 32 Pompili M, Serafini G, Innamorati M, Ambrosi E, Giordano G, Girardi P, et al. Antidepressants and suicide risk: a comprehensive overview. Pharmaceuticals 2010;3:2861-83.
    • 33 Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005;330:396.
    • 34 Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005;330:385.
    • 35 Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003;160:790-2.
    • 36 Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 2006;26:203-7.
    • 37 Healy D, Whitaker C. Antidepressants and suicide: risk-benefit conundrums. J Psychiatry Neurosci 2003;28:331.
    • 38 Anderson I, Ferrier I, Baldwin R, Cowen P, Howard L, Lewis G, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008;22:343-96.
    • © BMJ Publishing Group Ltd 2015
  • No related research data.
  • No similar publications.